he efficacy of alogliptin to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor and gastroprotective agents

he efficacy of alogliptin to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor and gastroprotective agents - The efficacy of alogliptin to gastrin and glycemic control

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011277

Enrollment

Registered

2013-07-26

Start date

2013-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with type 2 diabetes

Interventions

Alogliptin pioglitazone hydrochloride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type2 diabetes whose HbA1c is >6.4% under life style intervention and ordinal dosage of SU or metformin or alpha-glucosidase inhibitor treatment

Exclusion criteria

Exclusion criteria: diabetic ketosis severe infection before and after operation patients with severe trauma past history of allergy against alogliptin

Design outcomes

Primary

Measure	Time frame
Changes and %changes in gastrin and HbA1c after 6 months from baseline	—

Secondary

Measure	Time frame
Changes and %changes in the following parameters during the observation period Body weight Office blood pressure Serum creatinine HDL TG LDL	—

Countries

Japan

Contacts

Public ContactSyuuji Inoue

National Hospital Organization National Kochi Hospital, Kochi, Japan Division of Gastroenterology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026